Publications by authors named "James Rigas"

Claim this Profile
B
Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark.
Tapashi Dalvi, Mette Nørgaard, Jon P Fryzek, Naimisha Movva, Lars Pedersen, James Rigas

PLoS One· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark.
Elizabeth Hedgeman, Mette Nørgaard, Tapashi Dalvi, Lars Pedersen, Hanh Pham Hansen, James Rigas

Cancer Epidemiol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer.
Matthew B Schabath, Tapashi B Dalvi, Hongyue A Dai, Alan L Crim, Anita Midha, James R Rigas

Cancer Manag Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASTRIS: a global real-world study of osimertinib in >3000 patients with T790M positive non-small-cell lung cancer.
Filippo de Marinis, Yi-Long Wu, Gilberto de Castro, Gee-Chen Chang, Yuh-Min Chen, James R Rigas

Future Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States.
Ronan J Kelly, Ralph Turner, Yen-Wen Chen, James R Rigas, Ancilla W Fernandes

J Oncol Pract· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer.
Konstantin H Dragnev, Jeremy D Whyman, Cynthia K Hahn, Peter E Kebbekus, Sarah F Kokko, James R Rigas

J Thorac Dis· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, James R Rigas

Lancet Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.
Lakshmi Nayak, Lisa M DeAngelis, H Ian Robins, Ramaswamy Govindan, Shirish Gadgeel, James R Rigas

Cancer· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Monic Roengvoraphoj, Gregory J Tsongalis, Konstantin H Dragnev, James R Rigas

Cancer Treat Rev· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
Devin K Schweppe, James R Rigas, Scott A Gerber

J Proteomics· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.
Xiuyi Zhi, Wen Gao, Baohui Han, Yue Yang, Hui Li, James R Rigas

J Thorac Dis· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.
Candice C Black, Mary Jo Turk, Konstantin Dragnev, James R Rigas

Lung· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.
Tian Ma, Alexander D Fuld, James R Rigas, Anne E Hagey, Gary B Gordon

Chemotherapy· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Matthew D Wood, Bassem I Zaki, Stuart R Gordon, John E Sutton, Mikhail Lisovsky, James R Rigas

J Thorac Oncol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Jonathan D Marotti, Mary C Schwab, Nancy J McNulty, James R Rigas, Peter A DeLong

Diagn Cytopathol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
Trevor J Bayliss, Jeff T Smith, Michael Schuster, Konstantin H Dragnev, James R Rigas

Expert Opin Biol Ther· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Konstantin H Dragnev, Tian Ma, Jobin Cyrus, Fabrizio Galimberti, Vincent Memoli, James R Rigas

Cancer Prev Res (Phila)· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Ming-Sound Tsao, Akira Sakurada, Keyue Ding, Sarit Aviel-Ronen, Olga Ludkovski, James R Rigas

J Thorac Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.
Konstantin H Dragnev, Steven B Hardin, J Marc Pipas, Thomas H Davis, James R Rigas

Chemotherapy· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed in advanced non-small-cell lung cancer.
Alexander D Fuld, Konstantin H Dragnev, James R Rigas

Expert Opin Pharmacother· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Tianhong Li, Liawaty Ho, Bilal Piperdi, Tarek Elrafei, Fernando J Camacho, James R Rigas

Lung Cancer· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Helen J Ross, George R Blumenschein, Joseph Aisner, Nevena Damjanov, Afshin Dowlati, James R Rigas

Clin Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung cancer in a U.S. population with low to moderate arsenic exposure.
Julia E Heck, Angeline S Andrew, Tracy Onega, James R Rigas, Brian P Jackson

Environ Health Perspect· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
Ming-Sound Tsao, Sarit Aviel-Ronen, Keyue Ding, Davina Lau, Ni Liu, James Rigas

J Clin Oncol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current treatment paradigms for locally advanced non-small cell lung cancer.
James R Rigas, Karen Kelly

J Thorac Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis